Aripiprazole in the treatment of early-onset schizophrenia spectrum disorder: A case series in Korean children and adolescents
Abstract Objective : The aim of this case series was to assess the effectiveness and tol-erability of aripiprazole in Korean children and adolescents with early-onset schizophrenia spectrum (EOSS) disorder. Methods : The medical records of aripiprazole-treated patients with EOSS were retrospectively...
Gespeichert in:
| Veröffentlicht in: | Current therapeutic research 2009-04, Vol.70 (2), p.173-183 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 183 |
|---|---|
| container_issue | 2 |
| container_start_page | 173 |
| container_title | Current therapeutic research |
| container_volume | 70 |
| creator | Kim, Yeni, MD, PhD Cho, Soo-Churl, MD, PhD Shin, Min-Sup, PhD Kim, Jae-Won, MD, PhD Choi, Sang-Chul, MD Kim, Boong-Nyun, MD, PhD |
| description | Abstract Objective : The aim of this case series was to assess the effectiveness and tol-erability of aripiprazole in Korean children and adolescents with early-onset schizophrenia spectrum (EOSS) disorder. Methods : The medical records of aripiprazole-treated patients with EOSS were retrospectively reviewed. Changes in illness severity were measured using the Clinical Global Impression-Severity of Illness (CGI-S) and Clinical Global Impression-Improvement (CGI-I) scales. Results : Data from 22 children and adolescents were included (12 girls, 10 boys; mean [SD] age, 14.0 [2.4] years). The mean (SD) dosage of aripiprazole was 19.8 (9.4) mg/d (median, 18.7 mg/d; mode, 15, 30 mg/d), and the range of treatment duration was 21 to 838 days. Mean (SD) CGI-S score improved significantly from baseline to end point (from 5.7 [0.7] to 4.3 [1.4]; P < 0.001). Based on changes in chart-extracted CGI-I scores, significantly greater improvement was associated with negative symptoms compared with positive symptoms ( U = 25.5; P = 0.028; r = −0.47). Aripiprazole was discontinued due to insufficient effect in 5 patients (22.7%) and treatment-emergent adverse events in 3 patients (13.6%). Conclusion : The results from this small study suggest that aripiprazole was moderately effective in reducing psychotic symptoms in these Korean children and adolescents with EOSS. |
| doi_str_mv | 10.1016/j.curtheres.2009.04.007 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3967301</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0011393X09000393</els_id><sourcerecordid>1511822384</sourcerecordid><originalsourceid>FETCH-LOGICAL-c560t-9048554dbff928ac830669b8d52dbc05312a9bdcbb717a9c1a9755c771963c713</originalsourceid><addsrcrecordid>eNqNkktv1DAUhSMEokPhL4A3SN0kXMdJHLOoNKrKQ1RiAUjsLMe-YTxk7GAnlaaL_nYczTA8Vqwcyed89zjnZtkLCgUF2rzaFnoO0wYDxqIEEAVUBQB_kK1oy0UOjLKH2QqA0pwJ9vUsexLjFgAa4PxxdlZWTcvKsl1l9-tgRzsGdecHJNaRBCVTQDXt0E3E9wRVGPa5dxEnEvXG3vlxE9BZReKIegrzjhgbfTAYXpM10SoiiRgsxgX3wSeWI8k3mOQiyhmiTJoVdeLHp9mjXg0Rnx3P8-zLm-vPV-_ym49v31-tb3JdNzDlAqq2rivT9b0oW6VbBk0jutbUpek01IyWSnRGdx2nXAlNleB1rTmnomGaU3aeXR6449zt0CyzgxrkGOxOhb30ysq_b5zdyG_-VjLRcAYL4OIICP7HjHGSO5ueMAzKoZ-jpDWlbVmytkpSfpDq4GMM2J_GUJBLe3IrT-3JpT0JlUztJefzP1OefL_qSoKXR4GKWg19UE7b-FuXUjScLhHWBx2mf3prMcioLTqNxobUmTTe_keYy38YerDOprHfcY9x6-fgUmWSylhKkJ-WZVt2DUTas_TBfgKYHNVW</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1511822384</pqid></control><display><type>article</type><title>Aripiprazole in the treatment of early-onset schizophrenia spectrum disorder: A case series in Korean children and adolescents</title><source>DOAJ Directory of Open Access Journals</source><source>Elsevier ScienceDirect Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Kim, Yeni, MD, PhD ; Cho, Soo-Churl, MD, PhD ; Shin, Min-Sup, PhD ; Kim, Jae-Won, MD, PhD ; Choi, Sang-Chul, MD ; Kim, Boong-Nyun, MD, PhD</creator><creatorcontrib>Kim, Yeni, MD, PhD ; Cho, Soo-Churl, MD, PhD ; Shin, Min-Sup, PhD ; Kim, Jae-Won, MD, PhD ; Choi, Sang-Chul, MD ; Kim, Boong-Nyun, MD, PhD</creatorcontrib><description>Abstract Objective : The aim of this case series was to assess the effectiveness and tol-erability of aripiprazole in Korean children and adolescents with early-onset schizophrenia spectrum (EOSS) disorder. Methods : The medical records of aripiprazole-treated patients with EOSS were retrospectively reviewed. Changes in illness severity were measured using the Clinical Global Impression-Severity of Illness (CGI-S) and Clinical Global Impression-Improvement (CGI-I) scales. Results : Data from 22 children and adolescents were included (12 girls, 10 boys; mean [SD] age, 14.0 [2.4] years). The mean (SD) dosage of aripiprazole was 19.8 (9.4) mg/d (median, 18.7 mg/d; mode, 15, 30 mg/d), and the range of treatment duration was 21 to 838 days. Mean (SD) CGI-S score improved significantly from baseline to end point (from 5.7 [0.7] to 4.3 [1.4]; P < 0.001). Based on changes in chart-extracted CGI-I scores, significantly greater improvement was associated with negative symptoms compared with positive symptoms ( U = 25.5; P = 0.028; r = −0.47). Aripiprazole was discontinued due to insufficient effect in 5 patients (22.7%) and treatment-emergent adverse events in 3 patients (13.6%). Conclusion : The results from this small study suggest that aripiprazole was moderately effective in reducing psychotic symptoms in these Korean children and adolescents with EOSS.</description><identifier>ISSN: 0011-393X</identifier><identifier>EISSN: 1879-0313</identifier><identifier>DOI: 10.1016/j.curtheres.2009.04.007</identifier><identifier>PMID: 24683228</identifier><identifier>CODEN: CTCEA9</identifier><language>eng</language><publisher>New York, NY: EM Inc USA</publisher><subject>Adult and adolescent clinical studies ; aripiprazole ; Biological and medical sciences ; early-onset schizophrenia spectrum disorder ; Internal Medicine ; Medical Education ; Medical sciences ; Pharmacology. Drug treatments ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychoses ; Schizophrenia</subject><ispartof>Current therapeutic research, 2009-04, Vol.70 (2), p.173-183</ispartof><rights>Excerpta Medica Inc. All rights reserved.</rights><rights>2009 Excerpta Medica Inc. All rights reserved.</rights><rights>2009 INIST-CNRS</rights><rights>2009 The Authors. Published by Elsevier Inc. All rights reserved. 2009 Excerpta Medica Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c560t-9048554dbff928ac830669b8d52dbc05312a9bdcbb717a9c1a9755c771963c713</citedby><cites>FETCH-LOGICAL-c560t-9048554dbff928ac830669b8d52dbc05312a9bdcbb717a9c1a9755c771963c713</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3967301/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0011393X09000393$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,3536,27903,27904,53769,53771,65309</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21516714$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24683228$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kim, Yeni, MD, PhD</creatorcontrib><creatorcontrib>Cho, Soo-Churl, MD, PhD</creatorcontrib><creatorcontrib>Shin, Min-Sup, PhD</creatorcontrib><creatorcontrib>Kim, Jae-Won, MD, PhD</creatorcontrib><creatorcontrib>Choi, Sang-Chul, MD</creatorcontrib><creatorcontrib>Kim, Boong-Nyun, MD, PhD</creatorcontrib><title>Aripiprazole in the treatment of early-onset schizophrenia spectrum disorder: A case series in Korean children and adolescents</title><title>Current therapeutic research</title><addtitle>Curr Ther Res Clin Exp</addtitle><description>Abstract Objective : The aim of this case series was to assess the effectiveness and tol-erability of aripiprazole in Korean children and adolescents with early-onset schizophrenia spectrum (EOSS) disorder. Methods : The medical records of aripiprazole-treated patients with EOSS were retrospectively reviewed. Changes in illness severity were measured using the Clinical Global Impression-Severity of Illness (CGI-S) and Clinical Global Impression-Improvement (CGI-I) scales. Results : Data from 22 children and adolescents were included (12 girls, 10 boys; mean [SD] age, 14.0 [2.4] years). The mean (SD) dosage of aripiprazole was 19.8 (9.4) mg/d (median, 18.7 mg/d; mode, 15, 30 mg/d), and the range of treatment duration was 21 to 838 days. Mean (SD) CGI-S score improved significantly from baseline to end point (from 5.7 [0.7] to 4.3 [1.4]; P < 0.001). Based on changes in chart-extracted CGI-I scores, significantly greater improvement was associated with negative symptoms compared with positive symptoms ( U = 25.5; P = 0.028; r = −0.47). Aripiprazole was discontinued due to insufficient effect in 5 patients (22.7%) and treatment-emergent adverse events in 3 patients (13.6%). Conclusion : The results from this small study suggest that aripiprazole was moderately effective in reducing psychotic symptoms in these Korean children and adolescents with EOSS.</description><subject>Adult and adolescent clinical studies</subject><subject>aripiprazole</subject><subject>Biological and medical sciences</subject><subject>early-onset schizophrenia spectrum disorder</subject><subject>Internal Medicine</subject><subject>Medical Education</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychoses</subject><subject>Schizophrenia</subject><issn>0011-393X</issn><issn>1879-0313</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNqNkktv1DAUhSMEokPhL4A3SN0kXMdJHLOoNKrKQ1RiAUjsLMe-YTxk7GAnlaaL_nYczTA8Vqwcyed89zjnZtkLCgUF2rzaFnoO0wYDxqIEEAVUBQB_kK1oy0UOjLKH2QqA0pwJ9vUsexLjFgAa4PxxdlZWTcvKsl1l9-tgRzsGdecHJNaRBCVTQDXt0E3E9wRVGPa5dxEnEvXG3vlxE9BZReKIegrzjhgbfTAYXpM10SoiiRgsxgX3wSeWI8k3mOQiyhmiTJoVdeLHp9mjXg0Rnx3P8-zLm-vPV-_ym49v31-tb3JdNzDlAqq2rivT9b0oW6VbBk0jutbUpek01IyWSnRGdx2nXAlNleB1rTmnomGaU3aeXR6449zt0CyzgxrkGOxOhb30ysq_b5zdyG_-VjLRcAYL4OIICP7HjHGSO5ueMAzKoZ-jpDWlbVmytkpSfpDq4GMM2J_GUJBLe3IrT-3JpT0JlUztJefzP1OefL_qSoKXR4GKWg19UE7b-FuXUjScLhHWBx2mf3prMcioLTqNxobUmTTe_keYy38YerDOprHfcY9x6-fgUmWSylhKkJ-WZVt2DUTas_TBfgKYHNVW</recordid><startdate>20090401</startdate><enddate>20090401</enddate><creator>Kim, Yeni, MD, PhD</creator><creator>Cho, Soo-Churl, MD, PhD</creator><creator>Shin, Min-Sup, PhD</creator><creator>Kim, Jae-Won, MD, PhD</creator><creator>Choi, Sang-Chul, MD</creator><creator>Kim, Boong-Nyun, MD, PhD</creator><general>EM Inc USA</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20090401</creationdate><title>Aripiprazole in the treatment of early-onset schizophrenia spectrum disorder: A case series in Korean children and adolescents</title><author>Kim, Yeni, MD, PhD ; Cho, Soo-Churl, MD, PhD ; Shin, Min-Sup, PhD ; Kim, Jae-Won, MD, PhD ; Choi, Sang-Chul, MD ; Kim, Boong-Nyun, MD, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c560t-9048554dbff928ac830669b8d52dbc05312a9bdcbb717a9c1a9755c771963c713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adult and adolescent clinical studies</topic><topic>aripiprazole</topic><topic>Biological and medical sciences</topic><topic>early-onset schizophrenia spectrum disorder</topic><topic>Internal Medicine</topic><topic>Medical Education</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychoses</topic><topic>Schizophrenia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, Yeni, MD, PhD</creatorcontrib><creatorcontrib>Cho, Soo-Churl, MD, PhD</creatorcontrib><creatorcontrib>Shin, Min-Sup, PhD</creatorcontrib><creatorcontrib>Kim, Jae-Won, MD, PhD</creatorcontrib><creatorcontrib>Choi, Sang-Chul, MD</creatorcontrib><creatorcontrib>Kim, Boong-Nyun, MD, PhD</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Current therapeutic research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, Yeni, MD, PhD</au><au>Cho, Soo-Churl, MD, PhD</au><au>Shin, Min-Sup, PhD</au><au>Kim, Jae-Won, MD, PhD</au><au>Choi, Sang-Chul, MD</au><au>Kim, Boong-Nyun, MD, PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Aripiprazole in the treatment of early-onset schizophrenia spectrum disorder: A case series in Korean children and adolescents</atitle><jtitle>Current therapeutic research</jtitle><addtitle>Curr Ther Res Clin Exp</addtitle><date>2009-04-01</date><risdate>2009</risdate><volume>70</volume><issue>2</issue><spage>173</spage><epage>183</epage><pages>173-183</pages><issn>0011-393X</issn><eissn>1879-0313</eissn><coden>CTCEA9</coden><abstract>Abstract Objective : The aim of this case series was to assess the effectiveness and tol-erability of aripiprazole in Korean children and adolescents with early-onset schizophrenia spectrum (EOSS) disorder. Methods : The medical records of aripiprazole-treated patients with EOSS were retrospectively reviewed. Changes in illness severity were measured using the Clinical Global Impression-Severity of Illness (CGI-S) and Clinical Global Impression-Improvement (CGI-I) scales. Results : Data from 22 children and adolescents were included (12 girls, 10 boys; mean [SD] age, 14.0 [2.4] years). The mean (SD) dosage of aripiprazole was 19.8 (9.4) mg/d (median, 18.7 mg/d; mode, 15, 30 mg/d), and the range of treatment duration was 21 to 838 days. Mean (SD) CGI-S score improved significantly from baseline to end point (from 5.7 [0.7] to 4.3 [1.4]; P < 0.001). Based on changes in chart-extracted CGI-I scores, significantly greater improvement was associated with negative symptoms compared with positive symptoms ( U = 25.5; P = 0.028; r = −0.47). Aripiprazole was discontinued due to insufficient effect in 5 patients (22.7%) and treatment-emergent adverse events in 3 patients (13.6%). Conclusion : The results from this small study suggest that aripiprazole was moderately effective in reducing psychotic symptoms in these Korean children and adolescents with EOSS.</abstract><cop>New York, NY</cop><pub>EM Inc USA</pub><pmid>24683228</pmid><doi>10.1016/j.curtheres.2009.04.007</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0011-393X |
| ispartof | Current therapeutic research, 2009-04, Vol.70 (2), p.173-183 |
| issn | 0011-393X 1879-0313 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3967301 |
| source | DOAJ Directory of Open Access Journals; Elsevier ScienceDirect Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Adult and adolescent clinical studies aripiprazole Biological and medical sciences early-onset schizophrenia spectrum disorder Internal Medicine Medical Education Medical sciences Pharmacology. Drug treatments Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychoses Schizophrenia |
| title | Aripiprazole in the treatment of early-onset schizophrenia spectrum disorder: A case series in Korean children and adolescents |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T00%3A03%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Aripiprazole%20in%20the%20treatment%20of%20early-onset%20schizophrenia%20spectrum%20disorder:%20A%20case%20series%20in%20Korean%20children%20and%20adolescents&rft.jtitle=Current%20therapeutic%20research&rft.au=Kim,%20Yeni,%20MD,%20PhD&rft.date=2009-04-01&rft.volume=70&rft.issue=2&rft.spage=173&rft.epage=183&rft.pages=173-183&rft.issn=0011-393X&rft.eissn=1879-0313&rft.coden=CTCEA9&rft_id=info:doi/10.1016/j.curtheres.2009.04.007&rft_dat=%3Cproquest_pubme%3E1511822384%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1511822384&rft_id=info:pmid/24683228&rft_els_id=S0011393X09000393&rfr_iscdi=true |